These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

688 related items for PubMed ID: 33172454

  • 1. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
    Morieri ML, Avogaro A, Fadini GP, the DARWIN-T2D Network of the Italian Diabetes Society.
    Cardiovasc Diabetol; 2020 Nov 10; 19(1):190. PubMed ID: 33172454
    [Abstract] [Full Text] [Related]

  • 2. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
    Morieri ML, Perrone V, Veronesi C, Degli Esposti L, Andretta M, Plebani M, Fadini GP, Vigili de Kreutzenberg S, Avogaro A.
    Cardiovasc Diabetol; 2021 Jul 16; 20(1):144. PubMed ID: 34271920
    [Abstract] [Full Text] [Related]

  • 3. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS, Kennedy KF, Akeroyd JM, Morris PB, Bittner VA, Masoudi FA, Stone NJ, Petersen LA, Ballantyne CM.
    Circ Cardiovasc Qual Outcomes; 2018 May 16; 11(5):e004652. PubMed ID: 29748356
    [Abstract] [Full Text] [Related]

  • 4. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
    Arca M, Ansell D, Averna M, Fanelli F, Gorcyca K, Iorga ŞR, Maggioni AP, Paizis G, Tomic R, Catapano AL.
    Atherosclerosis; 2018 Apr 16; 271():120-127. PubMed ID: 29499359
    [Abstract] [Full Text] [Related]

  • 5. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W, Dippel FW, Theobald K, Gorcyca K, Iorga ŞR, Ansell D.
    Atherosclerosis; 2018 Jan 16; 268():99-107. PubMed ID: 29197254
    [Abstract] [Full Text] [Related]

  • 6. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
    Fischer LT, Hochfellner DA, Knoll L, Pöttler T, Mader JK, Aberer F.
    Cardiovasc Diabetol; 2021 Apr 24; 20(1):89. PubMed ID: 33894772
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.
    Singeisen H, Renström F, Laimer M, Lehmann R, Bilz S, Brändle M.
    Eur J Prev Cardiol; 2023 Oct 10; 30(14):1473-1481. PubMed ID: 37226890
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Unused potential of lipid-lowering therapy in very high-risk patients with atherosclerotic cardiovascular disease. A retrospective data analysis.
    Pohl SB, Engelbertz C, Reinecke H, Malyar NM, Meyborg M, Brix TJ, Varghese J, Gebauer K.
    Nutr Metab Cardiovasc Dis; 2024 Jul 10; 34(7):1670-1680. PubMed ID: 38664125
    [Abstract] [Full Text] [Related]

  • 11. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS).
    Blom DJ, Raal F, Amod A, Naidoo P, Lai YE, ICLPS SA study group.
    Cardiovasc J Afr; 2024 Jul 10; 30(1):15-23. PubMed ID: 30720848
    [Abstract] [Full Text] [Related]

  • 12. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J, Rajalingam T, Fossella J, Zhou H, Eisenberg N, Roche-Nagle G.
    Ann Vasc Surg; 2020 Nov 10; 69():197-205. PubMed ID: 32554202
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy.
    De Ferrari GM, Perna GP, Nicosia A, Guasti L, Casu G, Cuccia C, Picco F, Strazzella C, Totaro R, Cercone S, Canullo L, Horack M, Lautsch D, Gitt AK, Di Biase M.
    J Cardiovasc Med (Hagerstown); 2018 Sep 10; 19(9):485-490. PubMed ID: 29917002
    [Abstract] [Full Text] [Related]

  • 15. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study.
    Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, Murphy J, Banach M, De Servi S, Gaita D, Gouni-Berthold I, Hovingh GK, Jozwiak JJ, Jukema JW, Kiss RG, Kownator S, Iversen HK, Maher V, Masana L, Parkhomenko A, Peeters A, Clifford P, Raslova K, Siostrzonek P, Romeo S, Tousoulis D, Vlachopoulos C, Vrablik M, Catapano AL, Poulter NR, DA VINCI study.
    Eur J Prev Cardiol; 2021 Sep 20; 28(11):1279-1289. PubMed ID: 33580789
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
    Wang X, He Y, Wang T, Li C, Ma Z, Zhang H, Ma H, Zhao H.
    J Cardiovasc Pharmacol Ther; 2020 Jul 20; 25(4):307-315. PubMed ID: 31918567
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial.
    Shah NN, Ghazi L, Yamamoto Y, Kumar S, Martin M, Simonov M, Riello Iii RJ, Faridi KF, Ahmad T, Wilson FP, Desai NR.
    Circ Cardiovasc Qual Outcomes; 2024 May 20; 17(5):e010335. PubMed ID: 38634282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.